Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Cayman
CBL0137
72
CHF
CHF 72.00
In stock
CAY-19110-11 mgCHF 72.00
CAY-19110-55 mgCHF 246.00
CAY-19110-1010 mgCHF 454.00
Product Details | |
---|---|
Synonyms | CBLC137; Curaxin 137 |
Product Type | Chemical |
Properties | |
Formula | C21H24N2O2 |
MW | 336.4 |
CAS | 1197996-80-7 |
Purity Chemicals | ≥95% |
Appearance | A crystalline solid |
Declaration | Manufactured by Cayman Chemicals. |
Other Product Data |
Click here for Original Manufacturer Product Datasheet |
InChi Key | JKCSODVERGVDLT-UHFFFAOYSA-N |
Smiles | CC(C1=CC=C2C(C(C=C(C(C)=O)C=C3)=C3N2CCNC(C)C)=C1)=O |
Shipping and Handling | |
Shipping | BLUE ICE |
Long Term Storage | -20°C |
Documents | |
MSDS | Inquire |
Product Specification Sheet | |
Datasheet | Download PDF |
Description
Curaxins are small molecules that simultaneously activate p53 and inhibit NF-κB without causing detectable genotoxicity. CBL0137 is a water soluble and metabolically stable curaxin that activates p53 with an EC50 value of 0.37 µM and inhibits NF-κB with an EC50 of 0.47 µM. It functionally inactivates the facilitates chromatin transcription complex, driving the effects on p53 and NF-κB and promoting cancer cell death. CBL0137 has broad anticancer activity in mice when administered orally, eradicates drug-resistant cancer stem cells, and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.